Aigen Investment Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $473K | Buy |
+52,805
| New | +$473K | 0.06% | 413 |
|
|
2024
Q4 | – | Sell |
-28,661
| Closed | -$218K | – | 735 |
|
|
2024
Q3 | $218K | Buy |
28,661
+12,280
| +75% | +$93.3K | 0.04% | 559 |
|
|
2024
Q2 | $101K | Sell |
16,381
-24,720
| -60% | -$153K | 0.02% | 699 |
|
|
2024
Q1 | $209K | Buy |
41,101
+28,431
| +224% | +$144K | 0.05% | 536 |
|
|
2023
Q4 | $75.9K | Sell |
12,670
-140,804
| -92% | -$843K | 0.01% | 740 |
|
|
2023
Q3 | $1.09M | Buy |
153,474
+75,179
| +96% | +$532K | 0.2% | 146 |
|
|
2023
Q2 | $551K | Buy |
78,295
+35,772
| +84% | +$252K | 0.08% | 326 |
|
|
2023
Q1 | $355K | Buy |
+42,523
| New | +$355K | 0.05% | 392 |
|
|
2022
Q2 | – | Sell |
-11,172
| Closed | -$182K | – | 530 |
|
|
2022
Q1 | $182K | Buy |
+11,172
| New | +$182K | 0.03% | 473 |
|
|
2021
Q2 | – | Sell |
-21,588
| Closed | -$220K | – | 475 |
|
|
2021
Q1 | $220K | Buy |
+21,588
| New | +$220K | 0.03% | 514 |
|
|
2020
Q3 | – | Sell |
-13,984
| Closed | -$67K | – | 858 |
|
|
2020
Q2 | $67K | Buy |
+13,984
| New | +$67K | 0.01% | 770 |
|